C-reactive protein is associated with severity of thought and language dysfunction in patients with schizophrenia

References

• Lopresti AL, Maker GL, Hood SD, Drummond PD. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:102–111. doi:10.1016/j.pnpbp.2013.09.01724104186
   PubMed Web of Science ®Google Scholar
• Fernandes BS, Steiner J, Bernstein HG, et al. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry. 2016;21(4):554–564. doi:10.1038/mp.2015.8726169974
   PubMed Web of Science ®Google Scholar
• Fond G, d’Albis MA, Jamain S, et al. The promise of biological markers for treatment response in first-episode psychosis: a systematic review. Schizophr Bull. 2015;41(3):559–573. doi:10.1093/schbul/sbv00225759473
   PubMed Web of Science ®Google Scholar
• Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. 2007;93(1–3):261–265. doi:10.1016/j.schres.2007.03.02217490859
   PubMed Web of Science ®Google Scholar
• Faugere M, Micoulaud-Franchi JA, Alessandrini M, et al. Quality of life is associated with chronic inflammation in schizophrenia: a cross-sectional study. Sci Rep. 2015;5:10793. doi:10.1038/srep1079326041435
   PubMed Web of Science ®Google Scholar
• Fond G, Godin O, Brunel L, et al. Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set. J Affect Disord. 2016;191:209–215. doi:10.1016/j.jad.2015.11.01726674214
   PubMed Web of Science ®Google Scholar
• Frydecka D, Misiak B, Pawlak-Adamska E, et al. Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation. Eur Arch Psychiatry Clin Neurosci. 2015;265(6):449–459. doi:10.1007/s00406-014-0533-525214388
   PubMed Web of Science ®Google Scholar
• Micoulaud-Franchi JA, Faugere M, Boyer L, et al. Elevated C-reactive protein is associated with sensory gating deficit in schizophrenia. Schizophr Res. 2015;165(1):94–96. doi:10.1016/j.schres.2015.03.01825864954
   PubMed Web of Science ®Google Scholar
• Fond G, Lancon C, Auquier P, Boyer L. C-Reactive protein as a peripheral biomarker in schizophrenia. An updated systematic review. Front Psychiatry. 2018;9:392. doi:10.3389/fpsyt.2018.0039230190688
   PubMed Web of Science ®Google Scholar
• Dickerson F, Stallings C, Origoni A, et al. C-reactive protein is elevated in schizophrenia. Schizophr Res. 2013;143(1):198–202. doi:10.1016/j.schres.2012.10.04123218564
   PubMed Web of Science ®Google Scholar
• Fond G, Resseguier N, Schurhoff F, et al. Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort. Eur Arch Psychiatry Clin Neurosci. 2018;268(6):541–553. doi:10.1007/s00406-017-0847-129127503
   PubMed Web of Science ®Google Scholar
• Misiak B, Stanczykiewicz B, Kotowicz K, Rybakowski JK, Samochowiec J, Frydecka D. Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: a systematic review. Schizophr Res. 2018;192:16–29. doi:10.1016/j.schres.2017.04.01528416092
   PubMed Web of Science ®Google Scholar
• Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Additive effects of elevated C-reactive protein and exposure to herpes simplex virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr Res. 2012;134(1):83–88. doi:10.1016/j.schres.2011.10.00322048011
   PubMed Web of Science ®Google Scholar
• Bulzacka E, Boyer L, Schurhoff F, et al. Chronic peripheral inflammation is associated with cognitive impairment in schizophrenia: results from the multicentric FACE-SZ dataset. Schizophr Bull. 2016;42(5):1290–1302. doi:10.1093/schbul/sbw02927143795
   PubMed Web of Science ®Google Scholar
• Dorofeikova M, Neznanov N, Petrova N. Cognitive deficit in patients with paranoid schizophrenia: its clinical and laboratory correlates. Psychiatry Res. 2018;262:542–548. doi:10.1016/j.psychres.2017.09.04128951142
   PubMed Web of Science ®Google Scholar
• Hope S, Hoseth E, Dieset I, et al. Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls. Schizophr Res. 2015;165(2–3):188–194. doi:10.1016/j.schres.2015.04.00425956633
   PubMed Web of Science ®Google Scholar
• Joseph J, Depp C, Martin AS, et al. Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups. Schizophr Res. 2015;168(1–2):456–460. doi:10.1016/j.schres.2015.08.01926341579
   PubMed Web of Science ®Google Scholar
• Boozalis T, Teixeira AL, Cho RY, Okusaga O. C-Reactive protein correlates with negative symptoms in patients with schizophrenia. Front Public Health. 2017;5:360. doi:10.3389/fpubh.2017.0008129404313
   PubMed Web of Science ®Google Scholar
• Roche E, Creed L, MacMahon D, Brennan D, Clarke M. The epidemiology and associated phenomenology of formal thought disorder: a systematic review. Schizophr Bull. 2015;41(4):951–962. doi:10.1093/schbul/sbu12925180313
   PubMed Web of Science ®Google Scholar
• Roche E, Lyne JP, O’Donoghue B, et al. The factor structure and clinical utility of formal thought disorder in first episode psychosis. Schizophr Res. 2015;168(1–2):92–98. doi:10.1016/j.schres.2015.07.04926260080
   PubMed Web of Science ®Google Scholar
• Kerns JG, Berenbaum H. Cognitive impairments associated with formal thought disorder in people with schizophrenia. J Abnorm Psychol. 2002;111(2):211–224.12003444
   PubMed Web of Science ®Google Scholar
• Bora E, Yalincetin B, Akdede BB, Alptekin K. Neurocognitive and linguistic correlates of positive and negative formal thought disorder: a meta-analysis. Schizophr Res. 2019. doi:10.1016/j.schres.2019.05.025
   Web of Science ®Google Scholar
• Kircher T, Krug A, Stratmann M, et al. A rating scale for the assessment of objective and subjective formal Thought and Language Disorder (TALD). Schizophr Res. 2014;160(1–3):216–221. doi:10.1016/j.schres.2014.10.02425458572
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi:10.1093/schbul/13.2.2613616518
   PubMed Web of Science ®Google Scholar
• Andreasen NC. Scale for the assessment of thought, language, and communication (TLC). Schizophr Bull. 1986;12(3):473–482. doi:10.1093/schbul/12.3.4733764363
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Grove WM. Thought, language, and communication in schizophrenia: diagnosis and prognosis. Schizophr Bull. 1986;12(3):348–359. doi:10.1093/schbul/12.3.3483764356
   PubMed Web of Science ®Google Scholar
• Nagels A, Fahrmann P, Stratmann M, et al. Distinct neuropsychological correlates in positive and negative formal thought disorder syndromes: the thought and language disorder scale in endogenous psychoses. Neuropsychobiology. 2016;73(3):139–147. doi:10.1159/00044165727058747
   PubMed Web of Science ®Google Scholar
• Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 2007;149(1–3):267–271. doi:10.1016/j.psychres.2006.07.01117112596
   PubMed Web of Science ®Google Scholar
• Bolu A, Aydin MS, Akgun A, et al. Serum levels of high sensitivity C-reactive protein in drug-naive first-episode psychosis and acute exacerbation of schizophrenia. Clin Psychopharmacol Neurosci. 2019;17(2):244–249. doi:10.9758/cpn.2019.17.2.24430905124
   PubMed Web of Science ®Google Scholar
• Fawzi MH, Fawzi MM, Fawzi MM, Said NS. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res. 2011;190(1):91–97. doi:10.1016/j.psychres.2011.05.01021621854
   PubMed Web of Science ®Google Scholar
• Lin CH, Lane HY, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav. 2012;100(4):665–677. doi:10.1016/j.pbb.2011.03.02321463651
   PubMed Web of Science ®Google Scholar
• Li F, Tsien JZ. Memory and the NMDA receptors. N Engl J Med. 2009;361(3):302–303. doi:10.1056/NEJMcibr090205219605837
   PubMed Web of Science ®Google Scholar
• Campbell BM, Charych E, Lee AW, Moller T. Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci. 2014;8:12. doi:10.3389/fnins.2014.0001224567701
   PubMed Web of Science ®Google Scholar
• Najjar S, Pearlman DM, Devinsky O, Najjar A, Zagzag D. Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence. J Neuroinflammation. 2013;10:142. doi:10.1186/1742-2094-10-15124289502
   PubMed Web of Science ®Google Scholar
• Uranova NA, Zimina IS, Vikhreva OV, Krukov NO, Rachmanova VI, Orlovskaya DD. Ultrastructural damage of capillaries in the neocortex in schizophrenia. World J Biol Psychiatry. 2010;11(3):567–578. doi:10.3109/1562297090341418820109113
   PubMed Web of Science ®Google Scholar
• Adami C, Sorci G, Blasi E, Agneletti AL, Bistoni F, Donato R. S100B expression in and effects on microglia. Glia. 2001;33(2):131–142.11180510
   PubMed Web of Science ®Google Scholar
• Schwieler L, Larsson MK, Skogh E, et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia–significance for activation of the kynurenine pathway. J Psychiatry Neurosci. 2015;40(2):126–133.25455350
   PubMed Web of Science ®Google Scholar
• Kegel ME, Bhat M, Skogh E, et al. Imbalanced kynurenine pathway in schizophrenia. Int J Tryptophan Res. 2014;7:15–22. doi:10.4137/IJTR.S1680025288889
   PubMedGoogle Scholar
• Koshy Cherian A, Gritton H, Johnson DE, Young D, Kozak R, Sarter M. A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats. Neuropharmacology. 2014;82:41–48. doi:10.1016/j.neuropharm.2014.03.00424647121
   PubMed Web of Science ®Google Scholar
• Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13(7):465–477. doi:10.1038/nrn325722678511
   PubMed Web of Science ®Google Scholar
• Wu HQ, Okuyama M, Kajii Y, Pocivavsek A, Bruno JP, Schwarcz R. Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor. Schizophr Bull. 2014;40(Suppl 2):S152–S158. doi:10.1093/schbul/sbt15724562494
   PubMed Web of Science ®Google Scholar
• Magalhaes CA, Ferreira CN, Loures CMG, et al. Leptin, hsCRP, TNF-alpha and IL-6 levels from normal aging to dementia: relationship with cognitive and functional status. J Clin Neurosci. 2018;56:150–155. doi:10.1016/j.jocn.2018.08.02730150062
   PubMed Web of Science ®Google Scholar